v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities:    
Net (loss) income $ (3,287,051) $ 1,248,184
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization expense 1,276,283 1,031,584
Amortization of operating lease right-of-use asset 285,184 285,184
Co-commercialization investment loss 146,080 0
Share-based compensation 106,842 74,212
Increase (decrease) in non-cash contingent consideration (228,965) 44,976
Decrease in cash surrender value of life insurance policies over premiums paid 86,949 81,182
Noncash interest expense 5,173 5,362
Accounts receivable 2,682,802 1,213,541
Inventories, net 703,861 967,399
Other current assets and other assets 384,152 60,371
Operating lease liabilities (225,351) (219,493)
Accounts payable and other current liabilities (1,346,113) (600,043)
Other long-term liabilities (202,821) (293,942)
Net cash provided by operating activities 387,025 3,898,517
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]    
Additions to property and equipment 0 47,630
Increase in cash surrender value of life insurance policies (42,018) 0
Net (increase) decrease of investment in manufacturing 0 1,162,357
Additions to intangible assets 19,155 18,199
Net cash provided by (used in) investing activities (61,173) (1,228,186)
Cash flows from financing activities:    
Proceeds from ATM offering, net 0 5,266,334
Payments on line of credit 0 (10,035,437)
Cash settlement of contingent consideration (702,299) (511,131)
Payments made in connection with repurchase of common shares (61,001) (245,868)
Net cash used in financing activities (763,300) (5,526,102)
Net decrease in cash and cash equivalents (437,448) (2,855,771)
Cash and cash equivalents at beginning of period 11,444,693 17,964,184
Cash and cash equivalents at end of period $ 11,007,245 $ 15,108,413